Short answer
ClearPoint Neuro, Inc. (CLPT) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 fiscal 2026 results for quarter ended June 30, 2026.
ClearPoint Neuro, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the company’s financial results
- Results announcement dated August 3, 2026
Item 7.01 · Regulation FD Disclosure
- Updated investor presentation furnished under Regulation FD, creating a reference point for investor and analyst communications
- Presentation available on ClearPoint Neuro’s investor-relations website and filed as Exhibit 99.2
- Updated materials may signal revised corporate messaging, strategy, or outlook; investors should review Exhibit 99.2 for substantive changes
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $10.9M, up 18% YoY, driven by neurosurgery navigation and therapy revenue growth of 62% to $5.6M
- Biologics and drug delivery revenue fell 15% to $4.0M, reflecting lower biopharma trial-related product shipments
- Gross margin improved to 62% from 60%, but operating expenses rose 51% to $17.0M, widening net loss to $11.3M
- 2026 revenue guidance reset to $48.0M-$52.0M as investment shifts toward clinical support, CAL, focused ultrasound, robotics, and software
- Cash declined to $29.4M from $45.9M, with $15.0M used in operating activities and long-term notes payable of $50.2M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ClearPoint Neuro, Inc. 8-K filings
Get the next CLPT 8-K as it lands
Follow CLPT for push alerts, or ask the research agent what this filing means.